Table 1 Indications recommended by the National Comprehensive Cancer Network 2021, the European Society of Gynecological Oncology guidelines 2021 and the International Federation of Gynecology and Obstetrics cancer report 2018 for fertility-sparing treatment
From: Radiomics-based fertility-sparing treatment in endometrial carcinoma: a review
Guidelines | Histopathologic types and grades | MI | MRI/USa | Dilatation and curettage or endometrial biopsya | Informed consentb | Close follow-up | Outcomesc |
|---|---|---|---|---|---|---|---|
National Comprehensive Cancer Network 2021 | Grade 1 endometrial adenocarcinoma | No | Yes | Yes | Yes | Yes | TH/BSO |
European Society of Gynecological Oncology guidelines 2021 | Grade 1 endometrioid carcinoma or atypical hyperplasia/endometrioid intra-epithelial neoplasia | No | Yes | Yes | Yes | Yes | TH/BSO |
International Federation of Gynecology and Obstetrics cancer report 2018 | Grade 1 endometrioid carcinoma | No | Yes | - | Yes | Yes | TH/BSO |